ProtalixBio

Protalix (NYSE: $PLX) is dedicated to developing and commercializing therapeutic proteins with clinically improved profiles, produced by our ProCellEx® system

[ProtalixBio @Protalix_Bio]

Protalix BioTherapeutics Issues 2023 Letter to Stockholders https://t.co/tXpuI9UiI8 $PLX

[ProtalixBio @Protalix_Bio]

The FDA indicated in the BLA filing communication letter that the resubmitted BLA was considered a complete, class 2 response and set an action date of May 9, 2023, under the Prescription Drug User Fee Act (PDUFA). For more: https://t.co/BdqZwwh5wn $PLX

[ProtalixBio @Protalix_Bio]

Protalix and @ChiesiGRD today announced that the U.S. FDA has accepted the resubmitted Biologics License Application (BLA) for pegunigalsidase alfa (PRX-102) for the proposed treatment of adult patients with #Fabrydisease. https://t.co/BdqZwwh5wn $PLX

[ProtalixBio @Protalix_Bio]

Protalix's KOL event on #Fabrydisease and PRX-102 (pegunigalsidase alfa) will begin today, December 5, 2022 at 8:30 a.m. ET. Register for the event here: https://t.co/ICYfnXh4I9 $PLX

[ProtalixBio @Protalix_Bio]

Join us on Monday, December 5, 2022 at 8:30 a.m. EST for a KOL event on #Fabrydisease and PRX-102 (pegunigalsidase alfa). A live Q&A session will follow the formal presentations. For event details: https://t.co/ICYfnXyG6J $PLX

[LifeSci Advisors @LifeSciAdvisors]

Join us on December 5th at 8:30 AM ET for a KOL Event with @Protalix_Bio, featuring Myrl D. Holida (Physician Assistant), on Fabry Disease and Protalix’s investigational drug PRX-102 (pegunigalsidase alfa). Register here: https://t.co/N6UJdjUrHG $PLX

[ProtalixBio @Protalix_Bio]

During the KOL event, Myrl D. Holida, PA (@UIchildrens) will discuss the PRX-102 robust clinical program for the potential treatment of patients suffering from #Fabrydisease and Protalix leadership will provide a regulatory update regarding PRX-102. https://t.co/ICYfnXzdWh $PLX

[ProtalixBio @Protalix_Bio]

Save the date- Protalix will host a KOL event on #Fabrydisease and PRX-102 (pegunigalsidase alfa) on Monday, December 5th at 8:30 a.m. ET. To register for the event: https://t.co/ICYfnXh4I9 $PLX

[ProtalixBio @Protalix_Bio]

Protalix CEO Dror Bashan commented on the recent BLA resubmission to the FDA for PRX-102 for the treatment of adult patients with #Fabrydisease. For Q3 2022 and recent business highlights: https://t.co/VdWdNNahG4 $PLX

[ProtalixBio @Protalix_Bio]

Our CEO Dror Bashan commented on Protalix and @ChiesiGRD's BLA resubmission and shared goal of achieving regulatory approval and making PRX-102 (pegunigalsidase alfa) available to patients with #Fabrydisease in the U.S.: https://t.co/5IHqq6aFj1 $PLX

[ProtalixBio @Protalix_Bio]

To participate in today's conference call at 8:30 a.m. EST, please dial [phone] (domestic) or [phone] (international) with Conference ID:13734038 or access a live webcast here: https://t.co/wPuJg42r67 $PLX

[ProtalixBio @Protalix_Bio]

Protalix today reported financial results for the third quarter ended September 30, 2022 and provided a business update on recent corporate and regulatory developments. Management will host a conference call and webcast today at 8:30 a.m. EST. https://t.co/VdWdNMSGOw $PLX

[ProtalixBio @Protalix_Bio]

Pegunigalsidase alfa is a purposefully-designed, long-acting recombinant, PEGylated, cross-linked α-galactosidase-A investigational product candidate. Learn more: https://t.co/5IHqq5TCh1 $PLX #Fabrydisease

[ProtalixBio @Protalix_Bio]

Protalix and @ChiesiGRD today announced the resubmission on November 9, 2022 of a Biologics License Application (BLA) to the U.S.FDA for PRX-102 (pegunigalsidase alfa) for the treatment of adult patients with #Fabrydisease. https://t.co/5IHqq5TCh1 $PLX

[ProtalixBio @Protalix_Bio]

Protalix will host a conference call and live webcast to discuss financial results for Q3 2022 and provide a business update on Monday, November 14th at 8:30 a.m. EST. For dial-in and webcast details: https://t.co/i1nAzRHwns $PLX

[ProtalixBio @Protalix_Bio]

Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments Monday, November 14th at 8:30 a.m. EST. For details: https://t.co/i1nAzRHwns $PLX

[ProtalixBio @Protalix_Bio]

Protalix today announced that it will release its financial results for the third quarter 2022 and provide a business update on Monday, November 14, 2022. https://t.co/i1nAzRqtls $PLX

[ProtalixBio @Protalix_Bio]

Tune-in today, September 14th, at 11 a.m. EDT for Protalix CEO Dror Bashan's presentation at the @HCWCO 24th Annual Global Investment Conference: https://t.co/x6KWpKqBWU $PLX

[ProtalixBio @Protalix_Bio]

Protalix President and CEO Dror Bashan will present in person on Wednesday, September 14, 2022 at 11:00 a.m. EDT at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid conference. For webcast details: https://t.co/LctxUh8dBr $PLX

[ProtalixBio @Protalix_Bio]

Protalix CEO Dror Bashan will present at @HCWCO's 24th Annual Global Investment Conference, held from September 12-14, 2022. A webcast of the presentation will be available beginning Monday, September 12th at 7am ET. For details: https://t.co/URLCfbqxqi $PLX